Erasca, Inc. develops precision oncology therapies for cancers driven by the RAS/MAPK pathway. News on ERAS commonly centers on its RAS-targeting pipeline, including ERAS-0015, an investigational oral pan-RAS molecular glue evaluated in RAS-mutant solid tumors, and ERAS-4001, an oral pan-KRAS inhibitor for KRAS-mutant solid tumors.
Company updates frequently cover Phase 1 clinical data, dose-escalation results, trial collaborations and supply agreements, intellectual-property protection, development rights, public offering activity, financial results, and healthcare conference presentations. Recurring cancer settings in company disclosures include non-small cell lung cancer, pancreatic adenocarcinoma, colorectal cancer, and other RAS-mutant solid tumors.
Erasca, Inc. (Nasdaq: ERAS) has priced its upsized initial public offering at $16.00 per share for 18,750,000 shares, aiming for gross proceeds of $300.0 million. The shares are set to trade on Nasdaq starting July 16, 2021, with the offering closing on July 20, 2021, contingent on customary conditions. Underwriters have the option to purchase an additional 2,812,500 shares within 30 days. Erasca, focused on therapies for RAS/MAPK pathway-driven cancers, aims to leverage the funds for further development of its pipeline.